Who Paid My Doc
Ofirmev
Drug Acute Care
NDC 43825-102-01
General payments
$1,210,652
Research payments
$569,492
Through program year 2022, $1,210,652 in general payments and $569,492 in research payments were reported against Ofirmev (Acute Care).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $44,742 | 2 |
| 2021 | General | $34,789 | 11 |
| 2021 | Research | $34,079 | 2 |
| 2020 | General | $194,027 | 1,670 |
| 2020 | Research | $106,868 | 3 |
| 2019 | General | $981,836 | 6,148 |
| 2019 | Research | $383,803 | 12 |
Breakdown
The top 5 of 11 recipients; each share is of general payments naming this product in 2021.
Each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 7 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
7,829 general · 19 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.